biosciences/Lancet

Low-dose yellow fever vaccination in infants: a randomised, double-blind, non-inferiority trial.Kimathi D Juan-Giner A Bob NS Orindi B Namulwana ML Diatta A Cheruiyot S Fall G Dia M Hamaluba MM Nyehangane D Karanja HK Gitonga JN Mugo D Omuoyo DO Hussein M Oloo E Kamau N Wafula J Bendera J Silvester N Mwavita J Joshua M Thuranira JM Agababyona C Ngetsa C Aisha N Moki F Buluku T Munene M Mwanga-Amumpaire J Lutwama J Kayiwa J Kamaara E Barrett AD Kaleebu P Bejon P Sall AA Grais RF Warimwe GM
Lancet, (2026). 407:497-504

Regional action needed to halt antimalarial drug resistance in Africa.Martinez-Vega R Ishengoma DS Gosling R Rosenthal PJ Dondorp A Barnes KI Nsanzabana C Djimde AA Ochola-Oyier LI Tibenderana J Chimumbwa J Golassa L Kapologwe NA Mbacham WF Kamya MR Fidock DA Komatsu R von Seidlein L Dhorda M
Lancet, (2025). 405:7-10

Feasibility, safety, and impact of the RTS,S/AS01(E) malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi.Asante KP Mathanga DP Milligan P Akech S Oduro A Mwapasa V Moore KA Kwambai TK Hamel MJ Gyan T Westercamp N Kapito-Tembo A Njuguna P Ansong D Kariuki S Mvalo T Snell P Schellenberg D Welega P Otieno L Chimala A Afari EA Bejon P Maleta K Agbenyega T Snow RW Zulu M Chinkhumba J Samuels AM Malaria Vaccine Programme Evaluation Partners
Lancet, (2024). 403:1660-1670

Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.Datoo MS Dicko A Tinto H Ouedraogo JB Hamaluba M Olotu A Beaumont E Ramos Lopez F Natama HM Weston S Chemba M Compaore YD Issiaka D Salou D Some AM Omenda S Lawrie A Bejon P Rao H Chandramohan D Roberts R Bharati S Stockdale L Gairola S Greenwood BM Ewer KJ Bradley J Kulkarni PS Shaligram U Hill AVS R1/Matrix-M Phase 3 Trial Group
Lancet, (2024). 403:533-544

Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial.Juan-Giner A Kimathi D Grantz KH Hamaluba M Kazooba P Njuguna P Fall G Dia M Bob NS Monath TP Barrett AD Hombach J Mulogo EM Ampeire I Karanja HK Nyehangane D Mwanga-Amumpaire J Cummings DAT Bejon P Warimwe GM Grais RF
Lancet, (2021). 397:119-127

Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study.Hammitt LL Etyang AO Morpeth SC Ojal J Mutuku A Mturi N Moisi JC Adetifa IM Karani A Akech DO Otiende M Bwanaali T Wafula J Mataza C Mumbo E Tabu C Knoll MD Bauni E Marsh K Williams TN Kamau T Sharif SK Levine OS Scott JAG
Lancet, (2019). 393:2146-2154

Relation between falciparum malaria and bacteraemia in Kenyan children: a population-based, case-control study and a longitudinal study.Scott JA Berkley JA Mwangi I Ochola L Uyoga S Macharia A Ndila C Lowe BS Mwarumba S Bauni E Marsh K Williams TN
Lancet, (2011). 378:1316-23

Research priorities for malaria elimination.Marsh K
Lancet, (2010). 376:1626-7

Malaria in Africa: progress and prospects in the decade since the Abuja Declaration.Snow RW Marsh K
Lancet, (2010). 376:137-9

Bacteraemia in Kenyan children with sickle-cell anaemia: a retrospective cohort and case-control study.Williams TN Uyoga S Macharia A Ndila C McAuley CF Opi DH Mwarumba S Makani J Komba A Ndiritu MN Sharif SK Marsh K Berkley JA Scott JA
Lancet, (2009). 374:1364-70

Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya.O'Meara WP Bejon P Mwangi TW Okiro EA Peshu N Snow RW Newton CR Marsh K
Lancet, (2008). 372:1555-62

WHO, the Global Fund, and medical malpractice in malaria treatment.White N Nosten F Bjorkman A Marsh K Snow RW
Lancet, (2004). 363:1160

Variant surface antigen-specific IgG and protection against clinical consequences of pregnancy-associated Plasmodium falciparum malaria.Staalsoe T Shulman CE Bulmer JN Kawuondo K Marsh K Hviid L
Lancet, (2004). 363:283-9

Chlorproguanil-dapsone versus sulfadoxine-pyrimethamine for sequential episodes of uncomplicated falciparum malaria in Kenya and Malawi: a randomised clinical trial.Sulo J Chimpeni P Hatcher J Kublin JG Plowe CV Molyneux ME Marsh K Taylor TE Watkins WM Winstanley PA
Lancet, (2002). 360:1136-43

Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania.Mutabingwa T Nzila A Mberu E Nduati E Winstanley P Hills E Watkins W
Lancet, (2001). 358:1218-23

Diagnosis of acute bacterial meningitis in children at a district hospital in sub-Saharan Africa.Berkley JA Mwangi I Ngetsa CJ Mwarumba S Lowe BS Marsh K Newton CR
Lancet, (2001). 357:1753-7

A non-sense mutation in Cd36 gene is associated with protection from severe malaria.Pain A Urban BC Kai O Casals-Pascual C Shafi J Marsh K Roberts DJ
Lancet, (2001). 357:1502-3

Autoagglutination of malaria-infected red blood cells and malaria severity.Roberts DJ Pain A Kai O Kortok M Marsh K
Lancet, (2000). 355:1427-8

Aetiology, outcome, and risk factors for mortality among adults with acute pneumonia in Kenya.Scott JA Hall AJ Muyodi C Lowe B Ross M Chohan B Mandaliya K Getambu E Gleeson F Drobniewski F Marsh K
Lancet, (2000). 355:1225-30

Effect of phenobarbital on seizure frequency and mortality in childhood cerebral malaria: a randomised, controlled intervention study.Crawley J Waruiru C Mithwani S Mwangi I Watkins W Ouma D Winstanley P Peto T Marsh K
Lancet, (2000). 355:701-6